Clinical trialsCompany release

Recursion reports REC-4881 Phase 2 polyp data in FAP as Sanofi takes option

🇺🇸 Recursion Pharmaceuticals, Inc. (RXRX) · Mon 02 Nov 2026

Recursion's Q3 2026 update includes Phase 2 TUPELO results for REC-4881 in familial adenomatous polyposis, a Sanofi option exercise and cash runway extended into 2029.

Recursion Pharmaceuticals reported its third-quarter 2026 results on 2 November, alongside new Phase 2 TUPELO data for REC-4881, an oral MEK1/2 inhibitor being developed for familial adenomatous polyposis (FAP).

According to the company, the data showed reductions in polyp burden across the gastrointestinal tract, with no new safety signals identified. The summary available does not give figures for the size of the reductions, patient numbers or dosing details.

Recursion also provided an early Phase 1 update for REC-1245 in solid tumours. On partnering, it said Sanofi has optioned the first development candidate arising from the two companies' collaboration; financial terms were not stated in the material available.

On funding, the company said its expected cash runway now extends into 2029, following a follow-on offering in October 2026. It plans to start a registrational trial of REC-4881 in the second half of 2027, subject to discussions with the US Food and Drug Administration.

What it means for your team

  • The planned registrational REC-4881 trial in 2H 2027 depends on FDA discussions, so the endpoints and design agreed there will be the key regulatory milestone to watch.
  • Safety teams should note the company's statement of no new safety signals for an oral MEK1/2 inhibitor; detailed Phase 2 safety data will be needed to put this in context.
  • Sanofi's option on the first candidate from the collaboration shows the partnership advancing, though deal terms were not disclosed in the available material.

Company's press release (SEC filing): Recursion Pharmaceuticals, Inc. ↗

Article written by VigiEye from the official source (Recursion Pharmaceuticals, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Clinical trials All →